Bivalirudin
- Generic Name
- Bivalirudin
- Brand Names
- Angiomax
- Drug Type
- Small Molecule
- Chemical Formula
- C98H138N24O33
- CAS Number
- 128270-60-0
- Unique Ingredient Identifier
- TN9BEX005G
- Background
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activat...
- Indication
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
- Associated Conditions
- Thrombosis
- Associated Therapies
- -
Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial
- Conditions
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 250
- Registration Number
- NCT02448550
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Simplified Anti-Thrombotic Therapy for FFR
- Conditions
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Odessa Heart Institute
- Target Recruit Count
- 300
- Registration Number
- NCT02384070
Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART
- Conditions
- Interventions
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 6012
- Registration Number
- NCT02311231
- Locations
- 🇸🇪
Lund University, Lund, Sweden
ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial
- Conditions
- Interventions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 732
- Registration Number
- NCT01913483
- Locations
- 🇺🇸
Clearwater Cardiovascular and Interventional Consultants, Clearwater, Florida, United States
🇺🇸Deborah Heart and Lung Center, Browns Mills, New Jersey, United States
🇺🇸Stony Brook Medicine, Stony Brook, New York, United States
Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
- Conditions
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 100
- Registration Number
- NCT01848899
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
- Conditions
- Interventions
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Regado Biosciences, Inc.
- Target Recruit Count
- 3232
- Registration Number
- NCT01848106
- Locations
- 🇺🇸
Black Hills Cardiovascular Research, Rapid City, South Dakota, United States
BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.
- Conditions
- Interventions
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 2194
- Registration Number
- NCT01696110
- Locations
- 🇨🇳
1 st Hosp. of Anhui Med Univ., Hefei, Anhui, China
🇨🇳Anhui Provincial Hosp., Hefei, Anhui, China
🇨🇳3rd Hosp. of Beijing Univ., Beijing, Beijing, China
Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH
- Conditions
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 803
- Registration Number
- NCT01651780
- Locations
- 🇨🇦
Montreal Heart Institute, Montreal, Quebec, Canada
🇨🇦St. Paul´s Hospital Providence Health Care, Vancouver, Canada
🇫🇷Centre Hospitalier de Lyon, Bron, France
Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 204
- Registration Number
- NCT01555658
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences Policlinico Umberto I, Rome, Italy
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2015-05-13
- Target Recruit Count
- 1829
- Registration Number
- NCT01519518
- Locations
- 🇬🇧
Liverpool Heart and Chest Hospital, Liverpool, Merseyside, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.